The most potent HDAC inhibitors were cytotoxic against various cancer cell lines including J.γ1, a mutant Jurkat cell line resistant to the clinically used HDAC inhibitor suberanilohydroxamic acid (SAHA, vorinostat) and other 3-hydroxypyridin-2-thiones [37]. Here, HDAC9 is linked to cancer.